Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Goodwill (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Goodwill for 12 consecutive years, with $949000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill changed 0.0% year-over-year to $949000.0, compared with a TTM value of $949000.0 through Sep 2025, changed 0.0%, and an annual FY2024 reading of $949000.0, changed 0.0% over the prior year.
  • Goodwill was $949000.0 for Q3 2025 at CytomX Therapeutics, roughly flat from $949000.0 in the prior quarter.
  • Across five years, Goodwill topped out at $949000.0 in Q1 2021 and bottomed at $949000.0 in Q1 2021.
  • Average Goodwill over 5 years is $949000.0, with a median of $949000.0 recorded in 2021.
  • Peak annual rise in Goodwill hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Goodwill stood at $949000.0 in 2021, then changed by 0.0% to $949000.0 in 2022, then changed by 0.0% to $949000.0 in 2023, then changed by 0.0% to $949000.0 in 2024, then changed by 0.0% to $949000.0 in 2025.
  • Business Quant data shows Goodwill for CTMX at $949000.0 in Q3 2025, $949000.0 in Q2 2025, and $949000.0 in Q1 2025.